Selegiline as the primary treatment of Parkinson's disease — a long‐term double‐blind study
Identifieur interne : 001F92 ( Main/Exploration ); précédent : 001F91; suivant : 001F93Selegiline as the primary treatment of Parkinson's disease — a long‐term double‐blind study
Auteurs : V. V. Myllyl [Finlande] ; K. A. Sotaniemi [Finlande] ; P. Hakulinen [Finlande] ; O. M Ki-Lkola [Finlande] ; E. H. Heinonen [Finlande]Source :
- Acta Neurologica Scandinavica [ 0001-6314 ] ; 1997-04.
English descriptors
Abstract
Introduction – To assess the therapeutic efficacy of selegiline combined with levodopa in the long‐term treatment of Parkinson's disease (PD). Material and methods – A randomized, prospective, double‐blind study on 44 patients with PD needing levodopa therapy after the initial double‐blind treatment with placebo or selegiline was carried out. The patients were followed‐up for 5 years under combination therapy. Results – Selegiline induced a significant (P < 0.001) slowing in the need to increase the daily levodopa dose in order to compensate for the progression of the disease. After 5 years of combination therapy the mean dose of levodopa was on average 320 mg lower in the selegiline group (405 ± 59 mg vs 725 ± 78 mg). The difference in the levodopa doses between the two groups increased along with follow‐up time, as also the ratio of the levodopa doses (placebo/selegiline group). The number of daily levodopa doses needed to compensate for the occurrence of motor fluctuations was significantly lower in the selegiline group. The parkinsonian disability did not differ between the two groups because the clinical condition was kept as optimal as possible by adjusting the levodopa dosage. Nine patients in the placebo group needed initiation of additional dopaminergic therapy in comparison to one in the selegiline group (P=0.004). During the 5‐year follow‐up period 11 patients were withdrawn from the selegiline group, 7 due to adverse events. There was no difference in mortality between the two groups. Conclusion – Selegiline therapy offers beneficial long‐term effects in the treatment of PD.
Url:
DOI: 10.1111/j.1600-0404.1997.tb00101.x
Affiliations:
Links toward previous steps (curation, corpus...)
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Selegiline as the primary treatment of Parkinson's disease — a long‐term double‐blind study</title><author><name sortKey="Myllyl, V V" sort="Myllyl, V V" uniqKey="Myllyl V" first="V. V." last="Myllyl">V. V. Myllyl</name></author><author><name sortKey="Sotaniemi, K A" sort="Sotaniemi, K A" uniqKey="Sotaniemi K" first="K. A." last="Sotaniemi">K. A. Sotaniemi</name></author><author><name sortKey="Hakulinen, P" sort="Hakulinen, P" uniqKey="Hakulinen P" first="P." last="Hakulinen">P. Hakulinen</name></author><author><name sortKey="M Ki Kola, O" sort="M Ki Kola, O" uniqKey="M Ki Kola O" first="O." last="M Ki-Lkola">O. M Ki-Lkola</name></author><author><name sortKey="Heinonen, E H" sort="Heinonen, E H" uniqKey="Heinonen E" first="E. H." last="Heinonen">E. H. Heinonen</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:9DB39B007C8EE7AFE3D9D1B0520EC2A1037FE52E</idno><date when="1997" year="1997">1997</date><idno type="doi">10.1111/j.1600-0404.1997.tb00101.x</idno><idno type="url">https://api.istex.fr/document/9DB39B007C8EE7AFE3D9D1B0520EC2A1037FE52E/fulltext/pdf</idno><idno type="wicri:Area/Main/Corpus">001305</idno><idno type="wicri:Area/Main/Curation">001098</idno><idno type="wicri:Area/Main/Exploration">001F92</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Selegiline as the primary treatment of Parkinson's disease — a long‐term double‐blind study</title><author><name sortKey="Myllyl, V V" sort="Myllyl, V V" uniqKey="Myllyl V" first="V. V." last="Myllyl">V. V. Myllyl</name><affiliation wicri:level="1"><country xml:lang="fr">Finlande</country><wicri:regionArea>Department of Neurology, Oulu University Hospital, Oulu</wicri:regionArea><wicri:noRegion>Oulu</wicri:noRegion></affiliation></author><author><name sortKey="Sotaniemi, K A" sort="Sotaniemi, K A" uniqKey="Sotaniemi K" first="K. A." last="Sotaniemi">K. A. Sotaniemi</name><affiliation wicri:level="1"><country xml:lang="fr">Finlande</country><wicri:regionArea>Department of Neurology, Oulu University Hospital, Oulu</wicri:regionArea><wicri:noRegion>Oulu</wicri:noRegion></affiliation></author><author><name sortKey="Hakulinen, P" sort="Hakulinen, P" uniqKey="Hakulinen P" first="P." last="Hakulinen">P. Hakulinen</name><affiliation wicri:level="3"><country xml:lang="fr">Finlande</country><wicri:regionArea>Orion Corporation, Orion Pharma, Turku</wicri:regionArea><placeName><settlement type="city">Turku</settlement><region type="région" nuts="2">Finlande occidentale</region></placeName></affiliation></author><author><name sortKey="M Ki Kola, O" sort="M Ki Kola, O" uniqKey="M Ki Kola O" first="O." last="M Ki-Lkola">O. M Ki-Lkola</name><affiliation wicri:level="3"><country xml:lang="fr">Finlande</country><wicri:regionArea>Orion Corporation, Orion Pharma, Turku</wicri:regionArea><placeName><settlement type="city">Turku</settlement><region type="région" nuts="2">Finlande occidentale</region></placeName></affiliation></author><author><name sortKey="Heinonen, E H" sort="Heinonen, E H" uniqKey="Heinonen E" first="E. H." last="Heinonen">E. H. Heinonen</name><affiliation wicri:level="3"><country xml:lang="fr">Finlande</country><wicri:regionArea>Orion Corporation, Orion Pharma, Turku</wicri:regionArea><placeName><settlement type="city">Turku</settlement><region type="région" nuts="2">Finlande occidentale</region></placeName></affiliation></author></analytic><monogr></monogr><series><title level="j">Acta Neurologica Scandinavica</title><idno type="ISSN">0001-6314</idno><idno type="eISSN">1600-0404</idno><imprint><publisher>Blackwell Publishing Ltd</publisher><pubPlace>Oxford, UK</pubPlace><date type="published" when="1997-04">1997-04</date><biblScope unit="volume">95</biblScope><biblScope unit="issue">4</biblScope><biblScope unit="page" from="211">211</biblScope><biblScope unit="page" to="218">218</biblScope></imprint><idno type="ISSN">0001-6314</idno></series><idno type="istex">9DB39B007C8EE7AFE3D9D1B0520EC2A1037FE52E</idno><idno type="DOI">10.1111/j.1600-0404.1997.tb00101.x</idno><idno type="ArticleID">ANE211</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0001-6314</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Parkinson's disease</term><term>fluctuations in disability</term><term>levodopa</term><term>selegiline</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Introduction – To assess the therapeutic efficacy of selegiline combined with levodopa in the long‐term treatment of Parkinson's disease (PD). Material and methods – A randomized, prospective, double‐blind study on 44 patients with PD needing levodopa therapy after the initial double‐blind treatment with placebo or selegiline was carried out. The patients were followed‐up for 5 years under combination therapy. Results – Selegiline induced a significant (P < 0.001) slowing in the need to increase the daily levodopa dose in order to compensate for the progression of the disease. After 5 years of combination therapy the mean dose of levodopa was on average 320 mg lower in the selegiline group (405 ± 59 mg vs 725 ± 78 mg). The difference in the levodopa doses between the two groups increased along with follow‐up time, as also the ratio of the levodopa doses (placebo/selegiline group). The number of daily levodopa doses needed to compensate for the occurrence of motor fluctuations was significantly lower in the selegiline group. The parkinsonian disability did not differ between the two groups because the clinical condition was kept as optimal as possible by adjusting the levodopa dosage. Nine patients in the placebo group needed initiation of additional dopaminergic therapy in comparison to one in the selegiline group (P=0.004). During the 5‐year follow‐up period 11 patients were withdrawn from the selegiline group, 7 due to adverse events. There was no difference in mortality between the two groups. Conclusion – Selegiline therapy offers beneficial long‐term effects in the treatment of PD.</div></front></TEI><affiliations><list><country><li>Finlande</li></country><region><li>Finlande occidentale</li></region><settlement><li>Turku</li></settlement></list><tree><country name="Finlande"><noRegion><name sortKey="Myllyl, V V" sort="Myllyl, V V" uniqKey="Myllyl V" first="V. V." last="Myllyl">V. V. Myllyl</name></noRegion><name sortKey="Hakulinen, P" sort="Hakulinen, P" uniqKey="Hakulinen P" first="P." last="Hakulinen">P. Hakulinen</name><name sortKey="Heinonen, E H" sort="Heinonen, E H" uniqKey="Heinonen E" first="E. H." last="Heinonen">E. H. Heinonen</name><name sortKey="M Ki Kola, O" sort="M Ki Kola, O" uniqKey="M Ki Kola O" first="O." last="M Ki-Lkola">O. M Ki-Lkola</name><name sortKey="Sotaniemi, K A" sort="Sotaniemi, K A" uniqKey="Sotaniemi K" first="K. A." last="Sotaniemi">K. A. Sotaniemi</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001F92 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 001F92 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= ParkinsonV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= ISTEX:9DB39B007C8EE7AFE3D9D1B0520EC2A1037FE52E
|texte= Selegiline as the primary treatment of Parkinson's disease — a long‐term double‐blind study
}}
| This area was generated with Dilib version V0.6.23. |  |